System Xc- inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance.

[1]  Shota Yamamoto,et al.  Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy , 2021, International journal of molecular sciences.

[2]  V. Gebski,et al.  Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition , 2020, Cancer Research.

[3]  M. Ratajczak,et al.  Extracellular microvesicles/exosomes: discovery, disbelief, acceptance, and the future? , 2020, Leukemia.

[4]  Peng Huang,et al.  xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  Y. Zhu,et al.  Bone cancer-induced pain is associated with glutamate signalling in peripheral sensory neurons , 2020, Molecular pain.

[6]  Raghu Kalluri,et al.  The biology, function, and biomedical applications of exosomes , 2020, Science.

[7]  Gulden Camci-Unal,et al.  Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling , 2019, Leukemia.

[8]  Clotilde Théry,et al.  Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication , 2019, Nature Cell Biology.

[9]  R. Schots,et al.  Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts , 2018, Blood Cancer Journal.

[10]  James M. Lee,et al.  Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance , 2018, Clinical & translational immunology.

[11]  J. Norman,et al.  Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells , 2017, Nature Communications.

[12]  Yuan-Guo Zhou,et al.  Homeostasis of the Intraparenchymal-Blood Glutamate Concentration Gradient: Maintenance, Imbalance, and Regulation , 2017, Front. Mol. Neurosci..

[13]  B. Wall,et al.  Metabotropic glutamate receptors in cancer , 2017, Neuropharmacology.

[14]  B. Frey,et al.  Behavioural Effects of Using Sulfasalazine to Inhibit Glutamate Released by Cancer Cells: A Novel target for Cancer-Induced Depression , 2017, Scientific Reports.

[15]  C. Mancini,et al.  Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. , 2016, Blood.

[16]  P. Mantyh,et al.  The cystine/glutamate antiporter system xc− drives breast tumor cell glutamate release and cancer-induced bone pain , 2016, Pain.

[17]  X. Leleu,et al.  Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. , 2016, Cancer letters.

[18]  A. Sundan,et al.  Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells , 2016, Blood Cancer Journal.

[19]  D. Ribatti,et al.  Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression , 2016, The Journal of pathology.

[20]  R. Schots,et al.  Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma , 2016, Oncotarget.

[21]  K. Vanderkerken,et al.  The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells , 2015, Oncotarget.

[22]  G. Görgün,et al.  Targeting the bone marrow microenvironment in multiple myeloma , 2015, Immunological reviews.

[23]  O. De Wever,et al.  Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. , 2014, Blood.

[24]  B. Blot,et al.  Exosomes secreted by cortical neurons upon glutamatergic synapse activation specifically interact with neurons , 2014, Journal of extracellular vesicles.

[25]  H. Sontheimer,et al.  Sulfasalazine for brain cancer fits , 2012, Expert opinion on investigational drugs.

[26]  A. Palumbo,et al.  Multiple myeloma. , 2011, The New England journal of medicine.

[27]  P. Conn,et al.  Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.

[28]  Miguel C. Seabra,et al.  Rab27a and Rab27b control different steps of the exosome secretion pathway , 2010, Nature Cell Biology.

[29]  M. B. Mestre,et al.  TI-VAMP/VAMP7 and VAMP3/cellubrevin: two v-SNARE proteins involved in specific steps of the autophagy/multivesicular body pathways. , 2009, Biochimica et biophysica acta.

[30]  H. Sontheimer,et al.  Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor‐κB , 2009, Journal of neurochemistry.

[31]  W. Rzeski,et al.  Expression of glutamate receptor subunits in human cancers , 2009, Histochemistry and Cell Biology.

[32]  Satoru Takahashi,et al.  Redox Imbalance in Cystine/Glutamate Transporter-deficient Mice* , 2005, Journal of Biological Chemistry.

[33]  J. Howl,et al.  Group III metabotropic glutamate receptor activation inhibits Ca2+ influx and nitric oxide synthase activity in bone marrow stromal cells , 2005, Journal of cellular physiology.

[34]  Richard Pazdur,et al.  Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. , 2003, The oncologist.

[35]  K. Thielemans,et al.  Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. , 1997, British Journal of Cancer.